Literature DB >> 11303022

Demonstration of direct effects of growth hormone on neonatal cardiomyocytes.

C Lu1, G Schwartzbauer, M A Sperling, S U Devaskar, S Thamotharan, P D Robbins, C F McTiernan, J L Liu, J Jiang, S J Frank, R K Menon.   

Abstract

The cellular and molecular basis of growth hormone (GH) actions on the heart remain poorly defined, and it is unclear whether GH effects on the myocardium are direct or mediated at least in part via insulin-like growth factor (IGF-1). Here, we demonstrate that the cultured neonatal cardiomyocyte is not an appropriate model to study the effects of GH because of artifactual loss of GH receptors (GHRs). To circumvent this problem, rat neonatal cardiomyocytes were infected with a recombinant adenovirus expressing the murine GHR. Functional integrity of GHR was suggested by GH-induced activation of the cognate JAK2/STAT5, MAPK, and Akt intracellular pathways in the cells expressing GHR. Although exposure to GH resulted in a significant increase in the size of the cardiomyocyte and increased expression of c-fos, myosin light chain 2, and skeletal alpha-actin mRNAs, there were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH stimulation. In this model, GH increased incorporation of leucine, uptake of palmitic acid, and abundance of fatty acid transport protein mRNA. In contrast, GH decreased uptake of 2-deoxy-d-glucose and levels of Glut1 protein. Thus, in isolated rat neonatal cardiomyocytes expressing GHR, GH induces hypertrophy and causes alterations in cellular metabolic profile in the absence of demonstrable changes in IGF-1 mRNA, suggesting that these effects may be independent of IGF-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303022     DOI: 10.1074/jbc.M011647200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

2.  Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of gh with implications for the pathogenesis of diabetic nephropathy.

Authors:  P Anil Kumar; Kateryna Kotlyarevska; Prapai Dejkhmaron; Gaddameedi R Reddy; Chunxia Lu; Mahaveer S Bhojani; Ram K Menon
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

3.  Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease.

Authors:  Sherry Zhang; Chunxia Lu; Arun K Das; Anil K Pasupulati; Ram K Menon
Journal:  Growth Horm IGF Res       Date:  2018-10-04       Impact factor: 2.372

Review 4.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  Cardiovascular Disease in Acromegaly.

Authors:  Morali D Sharma; Anh V Nguyen; Spandana Brown; Richard J Robbins
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Apr-Jun

6.  Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway.

Authors:  Damien Gruson; Audrey Ginion; Noémie Decroly; Pascale Lause; Jean-Louis Vanoverschelde; Jean-Marie Ketelslegers; Luc Bertrand; Jean-Paul Thissen
Journal:  Heart Vessels       Date:  2011-04-20       Impact factor: 2.037

7.  Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation.

Authors:  Athanassia Sotiropoulos; Mickaël Ohanna; Cécile Kedzia; Ram K Menon; John J Kopchick; Paul A Kelly; Mario Pende
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-02       Impact factor: 11.205

8.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 9.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

10.  Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.

Authors:  Renata S Auriemma; Ludovica F S Grasso; Mariano Galdiero; Maurizio Galderisi; Claudia Pivonello; Chiara Simeoli; Maria Cristina De Martino; Rosario Ferrigno; Mariarosaria Negri; Cristina de Angelis; Rosario Pivonello; Annamaria Colao
Journal:  Endocrine       Date:  2016-06-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.